NOVO — Juli 2024
-
China opens door to Lilly's weight loss drug, intensifying Novo rivalry https://firstwordpharma.com/story/5877328
-
Novo Nordisk B
Novo Nordisk kan se frem til konkurrence om fedmepatienterne på det kinesiske marked, efter at myndighederne i landet har godkendt markedsføring af Eli Lillys Mounjaro.
Det sker, mindre end en måned efter at Novo Nordisk har fået Wegovy godkendt i landet, og omtrent to måneder efter godkendelsen af Mounjaro til diabetesbehandling.
Eli Lilly steg fredag 1,0 pct. til 857,47 dollar.
.\˙ MarketWire
-
-
SL..VH..Det er ingen nyhed, men en gammel artikel fra marts om Novo Nordisks nye tablet, Amycretin. Den har Troldmanden skrevet en del om.
-
Novo går nu aggressivt efter Eli Lillys Mounjaro/Zepbound https://proinvestor.com/boards/119537
-
Novo Nordisk justere i protokol til Amycretin klinisk studie https://proinvestor.com/boards/121087
-
Nye Amycretin fedme data ude - blow out INV347 data? https://proinvestor.com/boards/121266
-
-
Novo får britisk godkendelse af Wegovy mod hjertekarsygdomme https://borsen.dk/nyheder/virksomheder/novo-faar-britisk-godkendelse-af-wegovy-mod-hjertekarsygdomme?b_source=borsen&b_medium=row_0&b_campaign=list_1
-
Godmorgen

-
Novo får britisk godkendelse af Wegovy til forebyggelse af hjertekarsygdomme https://proinvestor.com/investornyt/1189313/novo-far-britisk-godkendelse-af-wegovy-til-forebyggelse-af-hjertekarsygdomme
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind